CN111380969A - Detection method for content of fluticasone furoate and related substances - Google Patents
Detection method for content of fluticasone furoate and related substances Download PDFInfo
- Publication number
- CN111380969A CN111380969A CN201811636446.8A CN201811636446A CN111380969A CN 111380969 A CN111380969 A CN 111380969A CN 201811636446 A CN201811636446 A CN 201811636446A CN 111380969 A CN111380969 A CN 111380969A
- Authority
- CN
- China
- Prior art keywords
- mobile phase
- acid
- content
- fluticasone furoate
- related substances
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/74—Optical detectors
Landscapes
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Steroid Compounds (AREA)
- Cosmetics (AREA)
Abstract
The invention provides a method for detecting the content of fluticasone furoate and related substances, which uses octadecylsilane chemically bonded silica as a filling agent, adopts an ultraviolet detector, detects the wavelength of 240nm-255nm, uses an acid solution with the concentration of 0.08% -0.12% as a mobile phase A, uses an acetonitrile solution of acid with the concentration of 0.03% -0.07% as a mobile phase B, and performs gradient elution. The invention has the advantages that the method can effectively separate and detect the furoic acid fluticasone and the process impurities and the degradation impurities thereof, and the specificity and the sensitivity meet the requirements; effectively control the level of related substances of the product and ensure the safety of medication.
Description
Technical Field
The invention belongs to the field of pharmaceutical analysis, and particularly relates to a method for detecting the content of fluticasone furoate and related substances.
Background
Fluticasone furoate (Fluticasone furoate) is an artificially synthesized corticosteroid derived from Fluticasone, belongs to glucocorticoid, shows high affinity with human glucocorticoid receptor in vitro, and has strong anti-inflammatory effect. Treating respiratory system diseases such as allergic rhinitis, asthma, COPD, etc.
Since the research on impurities of compounds is related to the safety of medicines, and the research and detection requirements on impurities in bulk drugs are higher and higher with the increase of the evaluation of medicines in recent years, the development of analysis methods thereof is particularly important. At present, both domestic and foreign documents and pharmacopoeias do not disclose a related substance analysis method of a furoic acid fluticasone raw material medicament and a preparation thereof. For bulk drugs, the impurities generally include process impurities and degradation impurities; different synthetic routes and processes produce different impurities, and the company separates and prepares the impurities of the furoic acid fluticasone, including: FFZ6, FFZ14, FFZ17, FZ11, FFZ1, FFZ16, FFZ3, FFZ5, FFZ12, FFZ15 and FFZ2, wherein the structural formulas of FFZ16, FFZ17, FFZ3 and FFZ15 are shown in the specification, and the structures of other impurities are confirmed.
The Asian Journal of Pharmaceutical and Clinical Research (2017),10(4),302-305 uses UV spectrophotometry to simultaneously determine the content of fluticasone furoate and vilanterol, but the method is UV spectrophotometry and cannot be used for detecting related substances of fluticasone furoate. Therefore, in order to better control the impurities of the medicine and further ensure the safety of the medicine, a set of related substance analysis methods needs to be established according to the physicochemical properties and the synthesis process of the medicine.
Disclosure of Invention
The invention relates to an analysis method of a corticosteroid bulk drug, in particular to a method for measuring related substances of fluticasone furoate.
The technical scheme of the invention is as follows:
a method for detecting the content of fluticasone furoate and related substances is characterized by comprising the following steps: octadecylsilane chemically bonded silica is used as a filling agent, an ultraviolet detector is adopted, the detection wavelength is 240nm-255nm, 0.08% -0.12% acid solution is used as a mobile phase A, acetonitrile solution containing 0.03% -0.07% acid is used as a mobile phase B, gradient elution is carried out according to the following table,
| time (minutes) | Mobile phase A | Mobile phase B |
| 0.0 | A1 | B1 |
| 28.0-30.0 | A2 | B2 |
| 31.0-32.0 | A2 | B2 |
Wherein, A1-58%, A2-28-32%; 38-42% of B1 and 68-72% of B2.
The detection method of the content of the fluticasone furoate and related substances is characterized by comprising the following steps of: octadecylsilane chemically bonded silica is used as a filling agent, an ultraviolet detector is adopted, the detection wavelength is 240nm-255nm, 0.08% -0.12% acid solution is used as a mobile phase A, acetonitrile solution containing 0.03% -0.07% acid is used as a mobile phase B, and gradient elution is carried out according to the following table:
| time (minutes) | Mobile phase A | Mobile phase B |
| 0.0 | A1 | B1 |
| 28.0-30.0 | A2 | B2 |
| 31.0-32.0 | A2 | B2 |
| 32.1-32.5 | A1 | B1 |
| 35.0-38.0 | A1 | B1 |
Wherein, A1-58%, A2-28-32%; 38-42% of B1 and 68-72% of B2.
The detection method of the content of the fluticasone furoate and related substances is characterized by comprising the following steps of: octadecylsilane chemically bonded silica is used as a filling agent, an ultraviolet detector is adopted, the detection wavelength is 240nm-255nm, 0.08% -0.12% acid solution is used as a mobile phase A, acetonitrile solution containing 0.03% -0.07% acid is used as a mobile phase B, gradient elution is carried out according to the following table,
| time (minutes) | Mobile phase A (%) | Mobile phase B (%) |
| 0 | 60 | 40 |
| 30.0 | 30 | 70 |
| 32.0 | 30 | 70 |
The detection method of the content of the fluticasone furoate and related substances is characterized by comprising the following steps of:
octadecylsilane chemically bonded silica is used as a filling agent, an ultraviolet detector is adopted, the detection wavelength is 240nm-255nm, 0.08% -0.12% acid solution is used as a mobile phase A, acetonitrile solution containing 0.03% -0.07% acid is used as a mobile phase B, and gradient elution is carried out according to the following table:
| time (minutes) | Mobile phase A (%) | Mobile phase B (%) |
| 0.0 | 60 | 40 |
| 30.0 | 30 | 70 |
| 32.0 | 30 | 70 |
| 32.1 | 60 | 40 |
| 35.0 | 60 | 40 |
The detection method of the content of the fluticasone furoate and related substances is characterized by comprising the following steps of: the acid in the mobile phase A and the mobile phase B is selected from trifluoroacetic acid, phosphoric acid or perchloric acid.
The detection method of the content of the fluticasone furoate and related substances is characterized by comprising the following steps of: the acid is trifluoroacetic acid.
The detection method of the content of the fluticasone furoate and related substances is characterized by comprising the following steps of: the mobile phase A is a 0.1% acid solution, and the mobile phase B is an acetonitrile solution containing 0.05% acid.
The concentration of the trifluoroacetic acid solution in the mobile phase A is 0.1%.
The concentration of the trifluoroacetic acid solution in the mobile phase B is 0.05%.
The method for detecting the content of the fluticasone furoate and related substances has the column temperature of 30-40 ℃.
The column temperature of the method for detecting the content of the furoic acid fluticasone and related substances is 35 ℃.
The flow rate of the detection method for the content of the fluticasone furoate and related substances is 1ml/min to 2.5 ml/min.
The flow rate of the method for detecting the content of the fluticasone furoate and related substances is 2 ml/min.
According to the detection method of the content of the fluticasone furoate and related substances, the detection wavelength is 245 nm.
A method for detecting the content of fluticasone furoate and related substances is used for detecting the raw material drug of fluticasone furoate.
A method for detecting the content of furoic acid fluticasone and related substances is used for detecting the medicinal preparation containing furoic acid fluticasone.
Compared with the prior art, the technical scheme of the application has the following advantages:
the method can effectively separate and detect the process impurities and the degradation impurities of the product, and the specificity and the sensitivity meet the requirements; effectively control the level of related substances of the product and ensure the safety of medication.
Drawings
FIG. 1 is a HPLC chart of inventive example 1
FIG. 2 is a HPLC chart of inventive example 2
Detailed Description
The invention will now be further described by way of the following examples, which are not intended to limit the scope of the invention in any way. It will be understood by those skilled in the art that equivalent substitutions for the technical features of the present invention, or corresponding modifications, can be made within the scope of the present invention.
Example 1
System suitability test
Taking FFZ2 reference substances, FFZ3 reference substances, FFZ6 reference substances, FFZ14 reference substances, FFZ1 reference substances, FFZ11 reference substances, FFZ12 reference substances, FFZ17 reference substances, FFZ5 reference substances, FFZ15 reference substances and FFZ16 reference substances in proper amount, precisely weighing and dissolving to obtain a mixed impurity reference substance, fixing the volume to the concentration of 1 mu g/ml, and taking fluticasone furoate reference substances to prepare 1mg/ml serving as a system applicability solution.
Blank solution: acetonitrile-water (50: 50);
sample introduction by high performance liquid chromatography
Chromatographic column using octadecylsilane chemically bonded silica as filler (Zorbax SB-C18, 150mm × 4.6.6 mm, 3.5 μm)
Mobile phase A: 0.1% trifluoroacetic acid solution;
mobile phase B: 0.05% trifluoroacetic acid in acetonitrile; the elution gradient is given in the following table,
the column temperature was 35 ℃; the flow rate was 2ml per minute; the detection wavelength is 245nm
| Time (minutes) | Mobile phase A (%) | Mobile phase B (%) |
| 0.0 | 60 | 40 |
| 30.0 | 30 | 70 |
| 32.0 | 30 | 70 |
| 32.1 | 60 | 40 |
| 35.0 | 60 | 40 |
The test results are shown in the attached figure 1, and the specific data are shown in the table 1:
TABLE 1 System suitability test results
Example 2
Taking a proper amount of a furoic acid fluticasone sample of FF021 batch, adding acetonitrile-water (50:50) to dissolve the furoic acid fluticasone sample to prepare a solution of 1mg/ml, and using the solution as a test sample solution; taking 1ml of the test solution, placing the test solution in a measuring flask of 100ml, adding methanol for dilution, fixing the volume to a scale, and shaking up to be used as a control solution.
Blank solution: acetonitrile-water (50: 50);
sample introduction by high performance liquid chromatography
Chromatographic column using octadecylsilane chemically bonded silica as filler (Zorbax SB-C18, 150mm × 4.6.6 mm, 3.5 μm)
Mobile phase A: 0.1% trifluoroacetic acid solution;
mobile phase B: 0.05% trifluoroacetic acid in acetonitrile; the elution gradient is given in the following table,
the column temperature was 38 ℃; flow rate was 1.5ml per minute; the detection wavelength is 245nm
| Time (minutes) | Mobile phase A (%) | Mobile phase B (%) |
| 0.0 | 60 | 40 |
| 30.0 | 30 | 70 |
| 32.0 | 30 | 70 |
| 32.1 | 60 | 40 |
| 35.0 | 60 | 40 |
The test results are shown in the attached figure 2, and only 4 impurities exist in the batch of samples, and the test results are shown in the table 2:
TABLE 2 test results of the samples of example 2
Example 3
System suitability test
Taking FFZ2 reference substances, FFZ3 reference substances, FFZ6 reference substances, FFZ14 reference substances, FFZ1 reference substances, FFZ11 reference substances, FFZ12 reference substances, FFZ17 reference substances, FFZ5 reference substances, FFZ15 reference substances and FFZ16 reference substances in proper amount, precisely weighing and dissolving to obtain a mixed impurity reference substance, fixing the volume to the concentration of 1 mu g/ml, and taking fluticasone furoate reference substances to prepare 1mg/ml serving as a system applicability solution.
Blank solution: acetonitrile-water (50: 50);
sample introduction by high performance liquid chromatography
Chromatographic column using octadecylsilane chemically bonded silica as filler (Zorbax SB-C18, 150mm × 4.6.6 mm, 3.5 μm)
Mobile phase A: 0.1% trifluoroacetic acid solution;
mobile phase B: 0.05% trifluoroacetic acid in acetonitrile; the elution gradient is given in the following table,
the column temperature is 30 ℃; flow rate was 1.5ml per minute; the detection wavelength is 245nm
| Time (minutes) | Mobile phase A (%) | Mobile phase B (%) |
| 0.0 | 58 | 42 |
| 30.0 | 28 | 72 |
| 32.0 | 28 | 72 |
| 32.1 | 58 | 42 |
| 35.0 | 58 | 42 |
The specific data of the test results are shown in Table 3:
TABLE 3 System suitability test results
Example 4
System suitability test
Taking FFZ2 reference substances, FFZ3 reference substances, FFZ6 reference substances, FFZ14 reference substances, FFZ1 reference substances, FFZ11 reference substances, FFZ12 reference substances, FFZ17 reference substances, FFZ5 reference substances, FFZ15 reference substances and FFZ16 reference substances in proper amount, precisely weighing and dissolving to obtain a mixed impurity reference substance, fixing the volume to the concentration of 1 mu g/ml, and taking fluticasone furoate reference substances to prepare 1mg/ml serving as a system applicability solution.
Blank solution: acetonitrile-water (50: 50);
sample introduction by high performance liquid chromatography
Chromatographic column using octadecylsilane chemically bonded silica as filler (Zorbax SB-C18, 150mm × 4.6.6 mm, 3.5 μm)
Mobile phase A: 0.1% trifluoroacetic acid solution;
mobile phase B: 0.05% trifluoroacetic acid in acetonitrile; the elution gradient is given in the following table,
the column temperature was 40 ℃; flow rate was 1.5ml per minute; the detection wavelength is 245nm
| Time (minutes) | Mobile phase A (%) | Mobile phase B (%) |
| 0.0 | 62 | 38 |
| 30.0 | 32 | 68 |
| 32.0 | 32 | 68 |
| 32.1 | 62 | 38 |
| 35.0 | 62 | 38 |
The specific data of the test results are shown in Table 4:
TABLE 4 System suitability test results
Example 5
System suitability test
Taking FFZ2 reference substances, FFZ3 reference substances, FFZ6 reference substances, FFZ14 reference substances, FFZ1 reference substances, FFZ11 reference substances, FFZ12 reference substances, FFZ17 reference substances, FFZ5 reference substances, FFZ15 reference substances and FFZ16 reference substances in proper amount, precisely weighing and dissolving to obtain a mixed impurity reference substance, fixing the volume to the concentration of 1 mu g/ml, and taking fluticasone furoate reference substances to prepare 1mg/ml serving as a system applicability solution.
Blank solution: acetonitrile-water (50: 50);
sample introduction by high performance liquid chromatography
Chromatographic column using octadecylsilane chemically bonded silica as filler (Zorbax SB-C18, 150mm × 4.6.6 mm, 3.5 μm)
Mobile phase A: 0.12% phosphoric acid solution;
mobile phase B: 0.07% phosphoric acid in acetonitrile; the elution gradient is given in the following table,
the column temperature is 30 ℃; flow rate was 1.5ml per minute; the detection wavelength is 245nm
| Time (minutes) | Mobile phase A (%) | Mobile phase B (%) |
| 0.0 | 58 | 42 |
| 30.0 | 28 | 72 |
| 32.0 | 28 | 72 |
| 32.1 | 58 | 42 |
| 35.0 | 58 | 42 |
The specific data of the test results are shown in table 5:
TABLE 5 System suitability test results
Example 6
System suitability test
Taking FFZ2 reference substances, FFZ3 reference substances, FFZ6 reference substances, FFZ14 reference substances, FFZ1 reference substances, FFZ11 reference substances, FFZ12 reference substances, FFZ17 reference substances, FFZ5 reference substances, FFZ15 reference substances and FFZ16 reference substances in proper amount, precisely weighing and dissolving to obtain a mixed impurity reference substance, fixing the volume to the concentration of 1 mu g/ml, and taking fluticasone furoate reference substances to prepare 1mg/ml serving as a system applicability solution.
Blank solution: acetonitrile-water (50: 50);
sample introduction by high performance liquid chromatography
Chromatographic column using octadecylsilane chemically bonded silica as filler (Zorbax SB-C18, 150mm × 4.6.6 mm, 3.5 μm)
Mobile phase A: 0.08% perchloric acid solution;
mobile phase B: 0.03% perchloric acid in acetonitrile; the elution gradient is given in the following table,
the column temperature was 40 ℃; flow rate was 1.5ml per minute; the detection wavelength is 245nm
The specific data of the test results are shown in Table 6:
TABLE 6 System suitability test results
While one embodiment of the present invention has been described in detail, the description is only a preferred embodiment of the present invention and should not be taken as limiting the scope of the invention. All equivalent changes and modifications made within the scope of the present invention shall fall within the scope of the present invention.
Claims (10)
1. A method for detecting the content of fluticasone furoate and related substances is characterized by comprising the following steps:
octadecylsilane chemically bonded silica is used as a filling agent, an ultraviolet detector is adopted, the detection wavelength is 240nm-255nm, 0.08% -0.12% acid solution is used as a mobile phase A, acetonitrile solution containing 0.03% -0.07% acid is used as a mobile phase B, gradient elution is carried out according to the following table,
Wherein, A1-58%, A2-28-32%; 38-42% of B1 and 68-72% of B2.
2. The method for detecting the content of fluticasone furoate and related substances according to claim 1, wherein the method comprises the following steps:
octadecylsilane chemically bonded silica is used as a filling agent, an ultraviolet detector is adopted, the detection wavelength is 240nm-255nm, 0.08% -0.12% acid solution is used as a mobile phase A, acetonitrile solution containing 0.03% -0.07% acid is used as a mobile phase B, and gradient elution is carried out according to the following table:
Wherein, A1-58%, A2-28-32%; 38-42% of B1 and 68-72% of B2.
3. The method for detecting the content of fluticasone furoate and related substances according to claim 1, wherein the method comprises the following steps:
octadecylsilane chemically bonded silica is used as a filling agent, an ultraviolet detector is adopted, the detection wavelength is 240nm-255nm, 0.08% -0.12% acid solution is used as a mobile phase A, acetonitrile solution containing 0.03% -0.07% acid is used as a mobile phase B, gradient elution is carried out according to the following table,
4. the method for detecting the content of fluticasone furoate and related substances according to claim 1, wherein the method comprises the following steps:
octadecylsilane chemically bonded silica is used as a filling agent, an ultraviolet detector is adopted, the detection wavelength is 240nm-255nm, 0.08% -0.12% acid solution is used as a mobile phase A, acetonitrile solution containing 0.03% -0.07% acid is used as a mobile phase B, and gradient elution is carried out according to the following table:
5. The method for detecting the content of fluticasone furoate and related substances according to any one of claims 1 to 4, wherein the method comprises the following steps: the acid in the mobile phase A and the mobile phase B is selected from trifluoroacetic acid, phosphoric acid or perchloric acid.
6. The method for detecting the content of fluticasone furoate and related substances according to claim 5, wherein the method comprises the following steps: the acid is trifluoroacetic acid.
7. The method for detecting the content of fluticasone furoate and related substances according to any one of claims 1 to 4 and 6, wherein the method comprises the following steps: the mobile phase A is a 0.1% acid solution, and the mobile phase B is an acetonitrile solution containing 0.05% acid.
8. The method for detecting the content of fluticasone furoate and related substances according to claims 1-4, wherein the method comprises the following steps: the detection wavelength was 245 nm.
9. The method for detecting the content of fluticasone furoate and related substances according to claims 1-4, wherein the method comprises the following steps: the column temperature is 30-40 ℃.
10. The method for detecting the content of fluticasone furoate and related substances according to claims 1-4, wherein the method comprises the following steps: the flow rate is 1 ml/min-2.5 ml/min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811636446.8A CN111380969A (en) | 2018-12-29 | 2018-12-29 | Detection method for content of fluticasone furoate and related substances |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811636446.8A CN111380969A (en) | 2018-12-29 | 2018-12-29 | Detection method for content of fluticasone furoate and related substances |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111380969A true CN111380969A (en) | 2020-07-07 |
Family
ID=71216525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811636446.8A Pending CN111380969A (en) | 2018-12-29 | 2018-12-29 | Detection method for content of fluticasone furoate and related substances |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111380969A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010016931A2 (en) * | 2008-08-07 | 2010-02-11 | Plus Chemicals Sa | Polymorphs of fluticasone furoate and process for preparation thereof |
| WO2012079275A1 (en) * | 2010-12-14 | 2012-06-21 | 浙江省天台县奥锐特药业有限公司 | Method for preparing fluticasone furoate |
| CN105012237A (en) * | 2015-08-10 | 2015-11-04 | 重庆华邦制药有限公司 | Fluticasone furoate nasal spray and preparation method thereof |
| CN106279341A (en) * | 2015-05-11 | 2017-01-04 | 正大天晴药业集团股份有限公司 | A kind of preparation method of fluticasone furoate |
-
2018
- 2018-12-29 CN CN201811636446.8A patent/CN111380969A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010016931A2 (en) * | 2008-08-07 | 2010-02-11 | Plus Chemicals Sa | Polymorphs of fluticasone furoate and process for preparation thereof |
| WO2012079275A1 (en) * | 2010-12-14 | 2012-06-21 | 浙江省天台县奥锐特药业有限公司 | Method for preparing fluticasone furoate |
| CN102558273A (en) * | 2010-12-14 | 2012-07-11 | 浙江省天台县奥锐特药业有限公司 | Method for preparing fluticasone furoate |
| CN106279341A (en) * | 2015-05-11 | 2017-01-04 | 正大天晴药业集团股份有限公司 | A kind of preparation method of fluticasone furoate |
| CN105012237A (en) * | 2015-08-10 | 2015-11-04 | 重庆华邦制药有限公司 | Fluticasone furoate nasal spray and preparation method thereof |
Non-Patent Citations (5)
| Title |
|---|
| ALLEN, A等: "Absolute bioavailability of intranasal fluticasone furoate in healthy subjects", CLINICAL THERAPEUTICS, vol. 29, no. 07 * |
| B BARDSLEY等: "Structure elucidation and spectroscopic analysis of photodegradants of the anti-rhinitis drug fluticasone furoate", ORGANIC & BIOMOLECULAR CHEMISTRY, vol. 08, no. 08, pages 1876 - 1880 * |
| SK MASIMUKKU等: "Development and Validation of Spectrophotometric Methods for Simultaneous Estimation of Vilanterol and Fluticasone Furoate in Pharmaceutical Formulations", ASIAN J PHARM CLIN RES, vol. 10, no. 04, pages 302 - 305 * |
| 张诚贤等: "UPLC-MS/MS法同时测定抗鼻炎外用制剂中掺加的9种化学药物", 中成药, vol. 39, no. 11, pages 2418 - 2421 * |
| 王卓春;: "维兰特罗关键中间体合成新方法", 广东化工, no. 05, pages 9 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107037153B (en) | The method that high performance liquid chromatography detects genotoxicity impurity in AL58805 bulk pharmaceutical chemicals or pharmaceutical preparation | |
| CN106896166B (en) | Analysis method in relation to substance in a kind of amber love song Ge Lieting raw material and its preparation | |
| CN104749269B (en) | A method of enantiomter impurity in Egelieting bulk pharmaceutical chemicals and preparation is measured using HPLC | |
| CN105527348B (en) | Separation analysis alogliptin benzoate preparation and its method in relation to substance | |
| CN112461953B (en) | Detection method of methyl bromide in 7-azoniabicyclo [2.2.1] heptane derivative | |
| CN115097035B (en) | LLTS intermediate and detection method and application of related impurities thereof | |
| CN105203658A (en) | Detection method for residual solvent in ezetimibe | |
| CN108008024A (en) | The detection method of genotoxicity impurity in doxofylline bulk pharmaceutical chemicals | |
| CN105806966A (en) | Quality control method for high optical purity folic acid preparation process | |
| CN111380969A (en) | Detection method for content of fluticasone furoate and related substances | |
| CN112129848A (en) | High performance liquid chromatography detection method for dimethylamino chloroethane hydrochloride related substances | |
| CN113049687A (en) | Method for detecting related substances of ambroxol hydrochloride raw material and injection | |
| Atici et al. | Synthesis and characterization of oxitropium bromide related substances and novel stability indicating HPLC methods | |
| CN108181386B (en) | Method for separating and measuring related substances in abiraterone acetate intermediate | |
| CN114414680B (en) | Method for measuring related substances in various small molecule anhydrides | |
| CN111007191B (en) | Content of sulfamethoxazole and/or trimethoprim, detection method of related substances thereof and application thereof | |
| CN106932522A (en) | The assay method of impurity compound I contents in a kind of nilotinib | |
| CN105974000B (en) | Purposes of the 7- benzoyl -1,3- Indolin-2-ones in nepafenac stability quality control | |
| CN110412164B (en) | Method for detecting related substances of mexiletine hydrochloride | |
| CN106187920A (en) | A kind of levo-cetirizine hydrochloride tablets have related substance and analyzing detecting method thereof | |
| CN111380970A (en) | Method for detecting content of methylprednisolone aceponate and related substances | |
| Zhang et al. | A full‐scale tracing study of “ghost peaks” encountered in impurity analysis of budesonide based on experimental operation inspection‐liquid chromatography/mass spectrometry fingerprint‐mechanism based stress studies integrated strategy | |
| CN112881538A (en) | Detection method for impurities and enantiomers in fudosteine and fudosteine tablets | |
| CN113820404B (en) | UPLC analysis method of ipratropium bromide aerosol | |
| CN106153756A (en) | A kind of detect the high performance liquid chromatography of rapamycin in everolimus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 300457 Tianjin Binhai New Area Development Zone West District Xinye nine Street North, Xinhuan West Road East. Applicant after: Tianjin Pharmaceutical Research Institute Co., Ltd Address before: 300457 Tianjin Binhai New Area Development Zone West District Xinye nine Street North, Xinhuan West Road East. Applicant before: TIANJIN PHARMACEUTICALS Group Corp. |
|
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |